Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22758764.v1

2023-01-01

Abstract:Supplementary Fig. S7 shows effect of PD-1 inhibition on treatment of tumors containing a B2m-/- population.

What problem does this paper attempt to address?

Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22758761.v1

2023-01-01

Abstract:Supplementary Fig. S8 shows CD8 T cell-dependent control of tumors containing a B2m-/- population with inactivated Rnf31 and Atg5 genes.
Supplementary Fig. S4 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22674276

2023-01-01

Abstract:Supplementary Fig. S4 shows differentially expressed genes revealed by RNA-seq analysis.
Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22674261

2023-01-01

Abstract:Supplementary Fig. S9 shows enhanced IFNg and TNFa expression by T cells and NK cells in Rnf31/Atg5-dKO tumors.
Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22674273

2023-01-01

Abstract:Supplementary Fig. S5 shows association of Atg5-KO and Rnf31/Atg5-dKO signatures with patient survival.
Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22674252

2023-01-01

Abstract:Supplementary Table S3: ## Raw count matrix of the RNA-seq data. ## Atg5-KO vs Ctrl-KO (Veh).
Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Shilpak Chatterjee,Paramita Chakraborty,Anusara Daenthanasanmak,Supinya Iamsawat,Gabriela Andrejeva,Libia A. Luevano,Melissa Wolf,Uday Baliga,Carsten Krieg,Craig C. Beeson,Meenal Mehrotra,Elizabeth G. Hill,Jeffery C. Rathmell,Xue-Zhong Yu,Andrew S. Kraft,Shikhar Mehrotra

DOI: https://doi.org/10.1158/1078-0432.22469031

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Tao Jiang,Qiqi Jin,Jiahao Wang,Fengying Wu,Jian Chen,Gongyan Chen,Yunchao Huang,Jianhua Chen,Ying Cheng,QiMing Wang,Yueyin Pan,Jianying Zhou,Jianhua Shi,Xingxiang Xu,LiZhu Lin,Wei Zhang,Yiping Zhang,Yunpeng Liu,Yong Fang,Jifeng Feng,Zhehai Wang,Sheng Hu,Jian Fang,Yongqian Shu,Jiuwei Cui,Yi Hu,Wenxiu Yao,Xingya Li,Xiaoyan Lin,Rui Wang,Yongsheng Wang,Wei Shi,Gaohua Feng,Jun Ni,Beibei Mao,Dandan Ren,Huaibo Sun,Henghui Zhang,Luonan Chen,Caicun Zhou,Shengxiang Ren

DOI: https://doi.org/10.1158/1078-0432.23791953.v1

2023-01-01

Abstract:Supplementary Materials
Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong-Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming‐Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497787

2023-01-01

Abstract:PDF file - 63K, Figure S1: Expression of RON and MET by breast cancer MCF-7, T-47D and ZR-75-1 cells.
Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22758755.v1

2023-01-01

Abstract:Supplementary Table S1: # Raw count of the genome-wide CRISPR screen for identifying T cell-mediated tumor killing in B2m-deficient cells. # MAGeCK results (Gene summary) for the genome-wide CRISPR screen from the B2m-deficient cells. # Gene log2FC in CRISPR screens from B2m-WT cells and B2m-KO cells. ## Common regulators of T cell mediated tumor killing in both B2m-WT and B2m-KO cells
Data from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.cd-22-1125

IF: 28.2

2023-01-01

Cancer Discovery

Abstract:Abstract Tumor heterogeneity is a major barrier to cancer therapy, including immunotherapy. Activated T cells can efficiently kill tumor cells following recognition of MHC class I (MHC-I)–bound peptides, but this selection pressure favors outgrowth of MHC-I–deficient tumor cells. We performed a genome-scale screen to discover alternative pathways for T cell–mediated killing of MHC-I–deficient tumor cells. Autophagy and TNF signaling emerged as top pathways, and inactivation of Rnf31 (TNF signaling) and Atg5 (autophagy) sensitized MHC-I–deficient tumor cells to apoptosis by T cell–derived cytokines. Mechanistic studies demonstrated that inhibition of autophagy amplified proapoptotic effects of cytokines in tumor cells. Antigens from apoptotic MHC-I–deficient tumor cells were efficiently cross-presented by dendritic cells, resulting in heightened tumor infiltration by IFNγ-and TNFα-producing T cells. Tumors with a substantial population of MHC-I–deficient cancer cells could be controlled by T cells when both pathways were targeted using genetic or pharmacologic approaches. Significance: Tumor heterogeneity is a major barrier to immunotherapy. We show that MHC-I–deficient tumor cells are forced into apoptosis by T cell–derived cytokines when TNF signaling and autophagy pathways are targeted. This approach enables T cell–mediated elimination of tumors with a substantial population of resistant, MHC-I–deficient tumor cells. This article is highlighted in the In This Issue feature, p. 1027
Figure S9 from Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells

Chien-Hsing Chang,Yang Wang,Rongxiu Li,Diane L. Rossi,Donglin Liu,Edmund A. Rossi,Thomas M. Cardillo,David M. Goldenberg

DOI: https://doi.org/10.1158/0008-5472.22414134.v1

2023-01-01

Abstract:. Effect of cPD-1 and T cells purified from PBMCs on single spheroids of MDA-MB-231 stimulated (A) or not (B) with IFN-gamma in the presence and absence of (E1)-3s
Supplementary Table S8 from CD38-Mediated Immunosuppression As a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Limo Chen,Lixia Diao,Yongyi Yang,Xiaohui Yi,B. Leticia Rodriguez,Yanli Li,Pamela Villalobos,Tina Cascone,Xi Liu,Tao Lin,Philip L. Lorenzi,Anfei Huang,Qiang Zhang,Di Peng,Jared J. Fradette,David H. Peng,Christin Ungewiss,Jonathon D. Roybal,Pan Tong,Junna Oba,Ferdinandos Skoulidis,Weiyi Peng,Brett W. Carter,Carl M. Gay,Fan Yu,Caleb A. Class,Jianxin Zhu,Jaime Rodriguez‐Canales,Masanori Kawakami,Lauren A. Byers,Scott E. Woodman,Vassiliki A. Papadimitrakopoulou,Ethan Dmitrovsky,Jing Wang,Stephen E. Ullrich,Ignacio I. Wistuba,John V. Heymach,F. Xiao-Feng Qin,Don L. Gibbons

DOI: https://doi.org/10.1158/2159-8290.22532330

2023-01-01

Abstract:Patient sample information as well as CD38 and PD-L1 IHC score in lung cancer tissue microarray bank TMA4.
Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells

Renpeng Ding,Shang Liu,Shanshan Wang,Huanyi Chen,Fei Wang,Qumiao Xu,Linnan Zhu,Xuan Dong,Ying Gu,Xiuqing Zhang,Cheng-Chi Chao,Qianqian Gao

DOI: https://doi.org/10.7150/thno.55075

IF: 11.6

2021-01-01

Theranostics

Abstract:Rationale: TCR-T cell therapy plays a critical role in the treatment of malignant cancers. However, it is unclear how TCR-T cells are affected by PD-L1 molecule in the tumor environment. We performed an in-depth evaluation on how differential expressions of tumor PD-L1 can affect the functionality of T cells.Methods: We used MART-1-specific TCR-T cells (TCR-TMART-1), stimulated with MART-127-35 peptide-loaded MEL-526 tumor cells, expressing different proportions of PD-L1, to perform cellular assays and high-throughput single-cell RNA sequencing.Results: Different clusters of activated or cytotoxic TCR-TMART-1 responded divergently when stimulated with tumor cells expressing different percentages of PD-L1 expression. Compared to control T cells, TCR-TMART-1 were more sensitive to exhaustion, and secreted not only pro-inflammatory cytokines but also anti-inflammatory cytokines with increasing proportions of PD-L1+ tumor cells. The gene profiles of chemokines were modified by increased expression of tumor PD-L1, which concurrently downregulated pro-inflammatory and anti-inflammatory transcription factors. Furthermore, increased expression of tumor PD-L1 showed distinct effects on different inhibitory checkpoint molecules (ICMs). In addition, there was a limited correlation between the enrichment of cell death signaling in tumor cells and T cells and increased tumor PD-L1 expression.Conclusion: Overall, though the effector functionality of TCR-T cells was suppressed by increased expression percentages of tumor PD-L1 in vitro, scRNA-seq profiles revealed that both the anti-inflammatory and pro-inflammatory responses were triggered by a higher expression of tumor PD-L1. This suggests that the sole blockade of tumor PD-L1 might inhibit not only the anti-inflammatory response but also the pro-inflammatory response in the complicated tumor microenvironment. Thus, the outcome of PD-L1 intervention may depend on the final balance among the highly dynamic and heterogeneous immune regulatory circuits.

medicine, research & experimental
Supplementary Figure S12 from CD24hiCD27+ Bregs Within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Huanhuan Huang,Yao,Lesang Shen,Jingxin Jiang,Ting Zhang,Jia Xiong,Jiaxin Li,Shanshan Sun,Siwei Zheng,Fang Jia,Jun Zhou,Xiuyan Yu,Wuzhen Chen,Jun Shen,Wenjie Xia,Xuan Shao,Qingqing Wang,Jian Huang,Chao Ni

DOI: https://doi.org/10.1158/1078-0432.24826170

2023-01-01

Abstract:Fig. S12. The addition of anti-PD1/PD-L1 to neoadjuvant chemotherapy improves the pCR rate of patients with mLNs.
Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy

Simon Eschweiler,James Clarke,Ciro Ramírez-Suástegui,Bharat Panwar,Ariel Madrigal,Serena J. Chee,Ioannis Karydis,Edwin Woo,Aiman Alzetani,Somaia Elsheikh,C. J. Hanley,G. J. Thomas,Peter S. Friedmann,Tilman Sanchez-Elsner,Ferhat Ay,Christian H. Ottensmeier,Pandurangan Vijayanand

DOI: https://doi.org/10.1038/s41590-021-00958-6

IF: 30.5

2021-06-24

Nature Immunology

Abstract:Immune-checkpoint blockade (ICB) has shown remarkable clinical success in boosting antitumor immunity. However, the breadth of its cellular targets and specific mode of action remain elusive. We find that tumor-infiltrating follicular regulatory T (TFR) cells are prevalent in tumor tissues of several cancer types. They are primarily located within tertiary lymphoid structures and exhibit superior suppressive capacity and in vivo persistence as compared with regulatory T cells, with which they share a clonal and developmental relationship. In syngeneic tumor models, anti-PD-1 treatment increases the number of tumor-infiltrating TFR cells. Both TFR cell deficiency and the depletion of TFR cells with anti-CTLA-4 before anti-PD-1 treatment improve tumor control in mice. Notably, in a cohort of 271 patients with melanoma, treatment with anti-CTLA-4 followed by anti-PD-1 at progression was associated with better a survival outcome than monotherapy with anti-PD-1 or anti-CTLA-4, anti-PD-1 followed by anti-CTLA-4 at progression or concomitant combination therapy.

immunology
Figure S1 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors

Sailing Shi,Shengqing Gu,Tong Han,Wubing Zhang,Lei Huang,Ziyi Li,Deng Pan,Jingxin Fu,Jun Ge,Myles Brown,Peng Zhang,Peng Jiang,Kai W. Wucherpfennig,X. Shirley Liu

DOI: https://doi.org/10.1158/1078-0432.22476180

2023-01-01

Abstract:Sup.Fig.1: The association between the CTL level and overall patient survival.
Supplementary Figure S15 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer

Hao Chen,Gregory M. Cresswell,Sarah Libring,Mitchell G. Ayers,Jinmin Miao,Zhong-Yin Zhang,Luis Solorio,Timothy L. Ratliff,Michael K. Wendt

DOI: https://doi.org/10.1158/2767-9764.22545144.v1

2023-01-01

Abstract:Growth factors and 3D culture environment induce PD-L1 in MBC cells.
Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951174

2024-01-01

Abstract:Supplementary Figure S5. Characterization of PD-1+ and PD-1- CD4+ T cells in PB and tumor.
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy

Rajasekharan Somasundaram,Thomas Connelly,Robin Choi,Hyeree Choi,Anastasia Samarkina,Ling Li,Elizabeth Gregorio,Yeqing Chen,Rohit Thakur,Mohamed Abdel-Mohsen,Marilda Beqiri,Meaghan Kiernan,Michela Perego,Fang Wang,Min Xiao,Patricia Brafford,Xue Yang,Xiaowei Xu,Anthony Secreto,Gwenn Danet-Desnoyers,Daniel Traum,Klaus H. Kaestner,Alexander C. Huang,Denitsa Hristova,Joshua Wang,Mizuho Fukunaga-Kalabis,Clemens Krepler,Fang Ping-Chen,Xiangyang Zhou,Alexis Gutierrez,Vito W. Rebecca,Prashanthi Vonteddu,Farokh Dotiwala,Shashi Bala,Sonali Majumdar,Harsh Dweep,Jayamanna Wickramasinghe,Andrew V. Kossenkov,Jorge Reyes-Arbujas,Kenisha Santiago,Tran Nguyen,Johannes Griss,Frederick Keeney,James Hayden,Brian J. Gavin,David Weiner,Luis J. Montaner,Qin Liu,Lukas Peiffer,Jürgen Becker,Elizabeth M. Burton,Michael A. Davies,Michael T. Tetzlaff,Kar Muthumani,Jennifer A. Wargo,Dmitry Gabrilovich,Meenhard Herlyn

DOI: https://doi.org/10.1038/s41467-020-20600-7

IF: 16.6

2021-01-12

Nature Communications

Abstract:Abstract Anti-PD-1 therapy is used as a front-line treatment for many cancers, but mechanistic insight into this therapy resistance is still lacking. Here we generate a humanized (Hu)-mouse melanoma model by injecting fetal liver-derived CD34 + cells and implanting autologous thymus in immune-deficient NOD- scid IL2Rγ null (NSG) mice. Reconstituted Hu-mice are challenged with HLA-matched melanomas and treated with anti-PD-1, which results in restricted tumor growth but not complete regression. Tumor RNA-seq, multiplexed imaging and immunohistology staining show high expression of chemokines, as well as recruitment of FOXP3 + Treg and mast cells, in selective tumor regions. Reduced HLA-class I expression and CD8 + /Granz B + T cells homeostasis are observed in tumor regions where FOXP3 + Treg and mast cells co-localize, with such features associated with resistance to anti-PD-1 treatment. Combining anti-PD-1 with sunitinib or imatinib results in the depletion of mast cells and complete regression of tumors. Our results thus implicate mast cell depletion for improving the efficacy of anti-PD-1 therapy.

multidisciplinary sciences
Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor

Chenyu Pi,Ping Jing,Bingyu Li,Yan Feng,Lijun Xu,Kun Xie,Tao Huang,Xiaoqing Xu,Hua Gu,Jianmin Fang

DOI: https://doi.org/10.3390/cancers14174134

2022-08-27

Cancers

Abstract:Immunotherapy is an effective method for tumour treatment. Anti-programmed cell death protein 1 (PD-1) and anti-programmed death-ligand 1 (PD-L1) monoclonal antibodies play a significant role in immunotherapy of most tumours; however, some patients develop drug resistance to PD-1/PD-L1 therapy. Cyclooxygenase-2 (COX2) is expressed in various solid tumours, and prostaglandin E2 (PGE2) drives the development of malignant tumours. We developed a drug-resistant B16F10 (B16F10-R) tumour mouse model through four rounds of selection in vivo. Subsequently, we investigated changes in PD-L1 expression and lymphocyte infiltration in B16F10-NR and B16F10-R tumours. Additionally, we explored the role of COX2 in acquired resistance to pembrolizumab, an anti-PD-1 treatment. Immune cell infiltration was significantly decreased in resistant tumours compared to B16F10-NR tumours; however, ptgs2 gene expression was significantly elevated in resistant tumours. Aspirin or celecoxib combined with pembrolizumab can effectively reverse tumour drug resistance. In addition, ptgs2 knockout or the use of the EP4 inhibitor E7046 abrogated drug resistance to anti-PD-1 treatment in B16F10-R tumour cells. Our study showed that inhibition of the COX2/PGE2/EP4 axis could increase the number of immune cells infiltrating the tumour microenvironment and recover drug-resistant tumour sensitivity to pembrolizumab. Thus, we highlight COX2 inhibition as a promising therapeutic target for drug-resistant tumours for future consideration.

oncology

Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines

Supplementary Fig. S4 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Data from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Figure S9 from Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells

Supplementary Table S8 from CD38-Mediated Immunosuppression As a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells

Supplementary Figure S12 from CD24hiCD27+ Bregs Within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy

Figure S1 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors

Supplementary Figure S15 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy

Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor